title: The challenges of community-directed treatment with ivermectin (CDTI) within the African Programme for Onchocerciasis Control (APOC).
abstract: The principal strategy adopted by the African Programme for Onchocerciasis Control (APOC), for the control of onchocerciasis in the 19 countries of Africa that now fall within the programme's remit, is that of community-directed treatment with ivermectin (CDTI). Halfway through its 12-year mandate, APOC has gathered enough information on the main challenges to guide its activities in Phase 2. An analysis of reports and other documents, emanating from consultants, scientists, monitors and national and project-level implementers, indicates that there are three broad categories of challenge: managerial; technical; and socio-political. Under these three categories, this review identifies the most pertinent concerns that APOC must address, during Phase 2, to enhance the prospects of establishing sustainable systems for ivermectin distribution. The major challenges include: (1) maintaining timely drug-collection mechanisms; (2) integrating CDTI with existing primary-healthcare services; (3) strengthening local health infrastructure; (4) achieving and maintaining an optimal treatment coverage; (5) establishing and up-scaling community self-monitoring; (6) designing and implementing operations research locally; (7) ensuring the adequacy of community-directed distributors; (8) increasing the involvement of local non-govemmental develop organizations in the programme; (9) achieving financial sustainability; (10) implementing equitable cost-recovery systems; and (11) engaging in effective advocacy. The implications of the challenges and suggestions about how they are being (or could be) addressed are also highlighted in this brief review, which should be of value to other programmes and agencies that may be contemplating the adoption of this unique strategy.
authors.affiliation: African Programme for Onchocerciasis Control (APOC), Ouagadougou, Burkina Faso. amazigouv@oncho.oms.bf
authors.forename: U V
authors.initials: UV
authors.lastname: Amazigo
authors.forename: W R
authors.initials: WR
authors.lastname: Brieger
authors.forename: M
authors.initials: M
authors.lastname: Katabarwa
authors.forename: O
authors.initials: O
authors.lastname: Akogun
authors.forename: M
authors.initials: M
authors.lastname: Ntep
authors.forename: B
authors.initials: B
authors.lastname: Boatin
authors.forename: J
authors.initials: J
authors.lastname: N'Doyo
authors.forename: M
authors.initials: M
authors.lastname: Noma
authors.forename: A
authors.initials: A
authors.lastname: Sékétéli
mesh_terms: D000349:Africa; D003153:Community Health Services / Q000458:organization & administration*; D005369:Filaricides / Q000627:therapeutic use*; D006801:Humans; D007391:International Cooperation; D007559:Ivermectin / Q000627:therapeutic use*; D015827:Onchocerciasis, Ocular / Q000517:prevention & control*
chemical_list: D005369:Filaricides; D007559:Ivermectin